NeuroLogica announces FDA clearance for inSPira HD: portable high
5 September 2009
The inSPira HD is a battery-powered, high resolution, portable SPECT
designed primarily for brain imaging. Its unique capabilities provide
high quality SPECT images wherever needed, including the clinic, ICU, OR
and emergency department. It is capable of imaging any radioisotope
energies between 80 – 200 keV for clinical applications such as
epilepsy, Parkinson’s, stroke and Alzheimer's dementia.
Neurologica says that features such as high resolution, convenience,
portability, and versatility set the inSPira HD apart from any other
SPECT imaging system available today.
Traditional systems whose basic principles have been around since the
1960’s continue to suffer from poor spatial and contrast resolution.
This has led to the term 'fuzzy” imaging with 5-10mm spatial resolution
in any one axis. The inSPira HD is revolutionary because it presents an
entirely new method of SPECT detection, acquisition, and reconstruction
which has been designed to approach 3mm spatial resolution.
“The medical community demands and deserves higher spatial and
contrast resolution,” says Dr Eric M Bailey, President and Chief
Executive Officer of NeuroLogica. “And we are pleased to provide that
capability at a price point that makes sense in today’s economic
environment. The inSPira HD is an entirely new type of SPECT imaging and
will play a key role in the treatment of neurological diseases going
Dr Colin Timothy McDonald, NeuroLogica’s Chief Medical Officer, said,
"The system is designed to push the limits of functional imaging in the
human brain. Chronic neurological diseases such as epilepsy, Parkinson’s
disease and Alzheimer’s dementia are difficult to study with traditional
3D non-functional neuroimaging modalities. This is because their
pathophysiology involves subtle and at times, submicroscopic
disturbances of form and function.
"The development of radiopharmaceuticals that can specifically target
these disease processes has caused a renewed interest and enthusiasm in
SPECT and PET functional neuroimaging. NeuroLogica Corporation, along
with its Medical Advisors, believes that the inSPira HD will prove
absolutely necessary for making the qualitative and quantitative
measurements necessary to determine the presence or absence of chronic
Bookmark this page